ArticleJAMA oncology2018
Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.
Article in JAMA oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.Transplantation and cellular therapy · 2022Guideline
- Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach.Progress in biomedical engineering (Bristol, England) · 2026Review
- Navigating Ethical Challenges in CAR-T Treatment.HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues · 2026Article
- Article
- Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood.Journal of translational medicine · 2026Article
- Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases.Journal of hematology & oncology · 2026Review
- mRNA-based CAR T cell engineering: Unmodified mRNA enables high CAR expression without innate immune activation in T cells.Molecular therapy. Nucleic acids · 2026Article
- Fabrication of boron-containing apatite ceramics via reaction sintering route and their response of lymphocytes for adoptive immunotherapy.Biomaterials and biosystems · 2026Article
- CAR-T cell therapy in rheumatic diseases: a review article.Clinical rheumatology · 2026Review
- Evaluation of DMSO-free cryopreservation reagent XT-Thrive for establishment of mesenchymal stem cell bank platform.Frontiers in bioengineering and biotechnology · 2026Article
- Is Pseudo-progression post-CAR T therapy real?Clinical hematology international · 2026Article
- Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer - results from the Tumor Profiler Melanoma project.NPJ precision oncology · 2025Article
- CAR-T cells targeting CD19 for the treatment of ANCA vasculitis.Clinical kidney journal · 2025Article
- Clearing the hurdles for CAR-T cell treatment.Nature reviews. Immunology · 2025Article
- Special Issue "The Promising Future of CAR-Based Therapies: A Matter of Molecular Details".International journal of molecular sciences · 2025Article
- Scalable and cost-effective CAR-T exosome therapies: challenges and future directions.Immunotherapy · 2025Review
- Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L).Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial.Molecular therapy. Oncology · 2025Article
- Biomaterial-Based Therapeutic Delivery of Immune Cells.Advanced healthcare materials · 2025Review
- Research Progress and Prospect of Nitrogen-containing Heterocycle in Anti-gastric Cancer Drugs: A Review.Current medicinal chemistry · 2025Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.